Get the Stockscreener App
3.465
3.48%
-0.125
Eledon Pharmaceuticals Inc stock is traded at $3.465, with a volume of 1.67M.
It is down -3.48% in the last 24 hours and up +19.90% over the past month.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
See More
Previous Close:
$3.59
Open:
$3.61
24h Volume:
1.67M
Relative Volume:
1.35
Market Cap:
$262.83M
Revenue:
-
Net Income/Loss:
$-45.62M
P/E Ratio:
-5.8294
EPS:
-0.5944
Net Cash Flow:
$-62.34M
1W Performance:
-12.94%
1M Performance:
+19.90%
6M Performance:
-0.43%
1Y Performance:
+3.12%
1-Day Range:
$3.40
$3.61
1-Week Range:
$3.40
$4.20
52-Week Range:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.465 | 262.83M | 0 | -45.62M | -62.34M | -0.5944 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Eledon Pharmaceuticals drops 10% on stock offering - MSN
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Eledon Pharmaceuticals (NASDAQ: ELDN) proposes 450M-share authorization increase - Stock Titan
Eledon Pharmaceuticals (ELDN) Partners with NewcelX to Enhance D - GuruFocus
5 Unstoppable Stocks That Could Double Your Money - Insider Monkey
Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money - Insider Monkey
NewcelX Ltd. Enhances Type 1 Diabetes Program with Strategic Collaboration with Eledon Pharmaceuticals - Quiver Quantitative
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - marketscreener.com
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration With Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - Moomoo
We're Not Very Worried About Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Rate - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 14.5% in March - MarketBeat
Big Picture: Can Eledon Pharmaceuticals Inc outperform under higher oil pricesWeekly Trade Review & AI Forecast for Swing Trade Picks - baoquankhu1.vn
EPS Watch: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingWeekly Market Outlook & Short-Term Swing Trade Alerts - baoquankhu1.vn
SG Americas Securities LLC Makes New Investment in Eledon Pharmaceuticals, Inc. $ELDN - MarketBeat
Can Eledon Pharmaceuticals (ELDN) Stock Beat the Market | Price at $3.15, Up 3.11%High Conviction Picks - Xã Thanh Hà
Can Eledon Pharmaceuticals Inc expand its profit marginsMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
Market Review: Can Eledon Pharmaceuticals Inc outperform under higher oil pricesRecession Risk & Reliable Intraday Trade Alerts - baoquankhu1.vn
Gainers Report: What hedge funds are buying Eledon Pharmaceuticals Inc2026 Trade Ideas & Safe Capital Growth Stock Tips - baoquankhu1.vn
After islet transplants, 10 diabetes patients stopped using insulin - Stock Titan
Insider Sell: Can Eledon Pharmaceuticals Inc outperform under higher oil pricesWeekly Stock Report & Technical Buy Zone Confirmations - baoquankhu1.vn
Eledon Pharmaceuticals Inc (2TK.SG) - Yahoo! Finance Canada
ELDN Forecast, Price Target & Analyst Ratings | ELEDON PHARMACEUTICALS INC (NASDAQ:ELDN) - ChartMill
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Rises By 30.3% - marketbeat.com
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
Geopolitics Watch: What hedge funds are buying Eledon Pharmaceuticals Inc2026 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Vanguard disaggregates holdings after realignment; Eledon (ELDN) showing 0 shares - Stock Titan
What is Noble Financial's Forecast for ELDN Q1 Earnings? - MarketBeat
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans? - Sahm
Midday Stock Roundup: RxSight Climbs 7% - Orange County Business Journal
Eledon Unveils New Type 1 Diabetes Data - Orange County Business Journal
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | 2TK | US28617K1016 - marketscreener.com
If You Invested $1,000 in Eledon Pharmaceuticals Inc (ELDN) - Stock Titan
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Eledon Pharmaceuticals Reports Positive 2025 Results for Tegoprubart in Transplant Trials and Receives FDA Orphan Drug Designation - Minichart
Eledon Pharmaceuticals, Inc. 2026 Annual Report: Business Overview, Risk Factors, and Strategic Focus on Immunology and Tegoprubart Development 29 - Minichart
Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
ELEDON PHARMACEUTICALS ($ELDN) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Eledon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results - The Manila Times
Eledon Pharmaceuticals 2025 net loss widens on higher R&D costs - TradingView
Eledon (NASDAQ: ELDN) 2025 results show higher R&D spend and cash - Stock Titan
Tegoprubart data and new orphan status headline Eledon (NASDAQ: ELDN) 2025 update - Stock Titan
Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings - TipRanks
ELDN PE Ratio & Valuation, Is ELDN Overvalued - Intellectia AI
Eledon reports insulin independence in islet transplant trial By Investing.com - Investing.com Australia
Leerink Maintains Outperform on ELDN (Eledon Pharmaceuticals) March 16, 2026 - Meyka
Eledon Pharmaceuticals (ELDN) Presents Promising Diabetes Trial Results - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative - Seeking Alpha
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eledon Pharmaceuticals Inc Stock (ELDN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hillson Jan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Kirk Allan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Katkin Keith | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
8,575 |
0 |
8,575 |
| Lee June | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Robinson James A. Jr. | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
4.01%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):